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INTRODUCTION
The family Dracaenaceae (Agavaceae) with more than
480 species has a distribution in the tropic and subtropic
dry climate regions throughout the world (Mimaki et al.,
1998). Many species of the genus Dracaena are used in
African traditional medicine for the treatment of a variety
of diseases. Dracaena mannii bark’s decoction is used by
the native people of the western highlands of Cameroon
against abdominal pains. Furthermore, the mixture of its
roots with “palm wine” is used in Cameroonian ethno-
medicine for the treatment of male impotency (Noumi et
al., 1998). The occurrence of steroidal saponins in several
Dracaenaceae plants is well documented (Mimaki et al.,
1999; Okunji et al., 1991). Steroidal saponins are a class
of natural products with strong biological and pharmaco-
logical effects. Some recently isolated steroidal saponins
have been shown to possess antifungal, cytotoxic and
antitumor effects (Zhang et al., 2006; Sautour et al; 2004;
2007) but only very few reports have been made regarding
their anti-inflammatory effect. In our ongoing search for
new and/or potentially bioactive saponins from Camerounian
medicinal plants (Tapondjou et al., 2002; 2003; 2005;
Teponno et al., 2006), the stem bark of D. mannii growing
in the western highlands of Cameroon has been studied.
In this study we found that the extracts of D. mannii
exhibited significant in vivo anti-inflammatory activity. In
the present paper we describe the isolation and structural
elucidation of steroidal saponins from D. mannii and their
structure-activity relationships on the in vivo anti-inflam-
matory test.
MATERIALS AND METHODS
General procedure
1H-NMR spectra were recorded in deuterated solvents
(CD3OD and pyridine-d5) on a Brucker AMX-400 Spectro-
meter at 400 MHz while 13C-NMR spectra were recorded
in the same solvents and the same apparatus at 100
MHz. All chemical shifts (d) are given in ppm units with
reference to tetramethylsilane (TMS) as internal standard
and the coupling constants (J) are in Hz. ESI-MS were
taken on a LCQ Thermofiningan Apparatus. IR spectra
were measured as a film on a KBr pellet using a FTIR-
8400S Shimadzu spectrometer. Column chromatography
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was performed using silica gel 60 Merck (0.040-0.063 mm)
and sephadex LH-20. TLC was carried out on precoated
Kieselgel 60 F254 (Merck) plates which were first viewed
with an ultraviolet lamp MULTIBAND UV- 254/365 nm for
fluorescent spots and thereafter developed by spraying
with 50% H2SO4 and heating for 10 mins at 110oC. Solvents
were distilled prior to use.
Plants material
The stem bark of Dracaena mannii was collected in
Dschang (West province of Cameroon) in March 2006
and authentified by Dr G. Achoundong of the Cameroon
National Herbarium, Yaoundé where specimens document-
ing the collection are deposited (Ref:12485/SRF/CAM).
Extraction and isolation
The dried and pulverized stem bark of Dracaena mannii
(2.5 Kg) was extracted three times (each time for 24 h)
with 95% EtOH. The filtrate obtained was concentrated
under reduced pressure to yield a dark residue (252 g).
Part of this extract (160 g) was suspended in water (300
mL) and extracted with EtOAc (26.3 g) and n-butanol
(66.8 g), respectively. Part of the n-butanol extract (64.1 g)
was subjected to column chromatography on silica gel,
with EtOAc-MeOH-H2O (85:15:5) as eluent, yielding four
fractions (A-D). The fraction (B, 11.9 g) with steroid saponins
was further subjected to repeated silica gel column chro-
matography (EtOAc-MeOH-H2O, 95:5:2) to afford com-
pounds 3 (20 mg), 1 (900 mg), and 4 (9.57 g). Part of the
EtOAc extract (24.4 g) was subjected to silica gel column
chromatography and elution was performed with hexane-
EtOAc increasing polarity to afford five main fractions (I-
V). From fraction II (Hexane-EtOAc (8:2)) (4.00 g), com-
pound 2 (152 mg) was obtained after further purification
over silica gel column chromatography eluted with hexane-
EtOAc (8:2) and recrystallisation in CH2Cl2.
Pennogenin-3-O-α-L-rhamnopyranosyl-(1→3)-β-D-
glucopyranoside (1)
White amorphous powder; ESI-MS: m/z 761 [M+Na]+, IR
 (cm-1): 3325, 2950, 1733, 1456, 1081; 1H-NMR (400
MHz, pyridine-d5):  0.55 (3H, d, J = 5.0 Hz, H-27), 0.77
(3H, s, H-19), 0.82 (3H, s, H-18), 1.08 (3H, d, J = 7.0 Hz,
H-21), 1.57 (3H, d, J = 6.0 Hz, H-6''), 3.74 (1H, m, H-3),
4.76 (1H, d, J = 7.5 Hz, H-1'), 5.15 (1H, brs, H-6), 6.10
(1H, brs, H-1''; 13C-NMR (100 MHz, pyridine-d5) : Table I.
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Table I. 13C-NMR data (ppm, 125 MHz) of compounds 1-4 isolated from the Dracaena mannii stem bark
Carbon 1 2 3 4 Carbon 1 2 3 4
1 37.5 38.5 37.8 37.4 24 28.7 29.4 29.1 28.6
2 30.0 33.2 30.3 29.9 25 30.3 33.3 30.7 30.3
3 78.1 72.4 78.1 77.9 26 66.6 67.7 67.0 66.7
4 39.2 43.0 38.9 38.6 27 17.1 17.5 17.6 17.2
5 140.7 142.3 141.0 140.7 3-O-Gluc 1' 102.1 105.9 99.8
6 121.7 122.1 122.2 121.7 3-O-Gluc 2' 75.6 75.9 78.2
7 32.2 32.3 32.4 31.7 3-O-Gluc 3' 83.5 78.7 87.4
8 32.4 32.8 32.7 32.0 3-O-Gluc 4' 69.8 71.8 70.5
9 50.0 51.4 50.5 50.1 3-O-Gluc 5' 78.2 78.4 77.7
10 36.9 37.7 37.4 37.0 3-O-Gluc 6' 62.4 62.9 62.2
11 20.9 21.7 21.2 20.8 3'-O-Rha 1'' 102.8 102.5
12 31.9 32.5 32.1 31.9 3'-O-Rha 2'' 72.5 72.3
13 45.0 45.5 45.5 45.0 3'-O-Rha 3'' 72.6 72.5
14 53.0 53.9 53.3 52.9 3'-O-Rha 4'' 74.1 73.5
15 31.9 31.2 32.1 31.9 3'-O-Rha 5'' 69.6 69.8
16 89.9 90.6 90.3 89.9 3'-O-Rha 6'' 18.6 18.3
17 90.0 91.2 90.5 90.0 2'-O-Rha 1''' 103.7
18 17.1 17.4 17.5 17.0 2'-O-Rha 2''' 72.4
19 19.3 18.8 19.7 19.3 2'-O-Rha 3''' 72.7
20 44.7 45.8 45.1 44.7 2'-O-Rha 4''' 73.7
21 9.6 9.0 10.1 9.6 2'-O-Rha 5''' 69.8
22 109.7 110.9 110.2 109.7 2'-O-Rha 6''' 18.5
23 32.4 32.0 32.7 32.3
Solvent C5D5N CD3OD C5D5N C5D5N Solvent C5D5N CD3OD C5D5N C5D5N
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Pennogenin (2)
White amorphous powder; ESI-MS: m/z 883 [2M+Na]+,
413 [M-H-H2O]-; IR  (cm-1): 3531, 2871, 1728, 1456,
1057; 1H-NMR (400 MHz, CD3OD):  0.80 (3H, d, J = 5.6
Hz, H-27), 0.84 (3H, s, H-18), 0.89 (3H, d, J = 7.1 Hz, H-
21), 1.07 (3H, s, H-19), 3.26 (1H, m, H-3), 3.86 (1H, t, J =
7.8, H-16), 5.20 (1H, brs, H-6); 13C-NMR (100 MHz,
CD3OD) : Table I.
Pennogenin-3-O-β-D-glucopyranoside (floribundasap-
onin A) (3)
White amorphous powder; ESI-MS: m/z 615 [M+Na]+; IR
 (cm-1): 3415, 2971, 1725, 1430, 1050; 1H-NMR (400
MHz, pyridine-d5):  0.70 (3H, d, J = 5.7 Hz, H-27), 0.98
(3H, s, H-18), 1.09 (3H, s, H-19), 1.26 (3H, d, J = 7.2 Hz,
H-21), 1.57 (3H, d, J = 6.0 Hz, H-6”), 3.85 (1H, m, H-3),
4.90 (1H, d, J = 7.6 Hz, H-1'), 5.28 (1H, brs, H-6); 13C-
NMR (100 MHz, pyridine-d5) : Table I.
Pennogenin-3-O-α-L-rhamnopyranosyl-(1→2)-[α-L-
rhamnopyranosyl-(1→3)]-β-D-glucopyranoside
(spiroconazole A) (4)
White amorphous powder; ESI-MS: m/z 883 [M - H]-, 737
[M - H - 146], 591 [M - H - 2  146]; IR  (cm-1): 3435,
3006, 2918, 1660, 1437, 1406, 1029, 955, 706; 1H-NMR
(400 MHz, pyridine-d5):  0.55 (3H, d, J = 5.5 Hz, H-27),
0.82 (3H, s, H-19), 0.94 (3H, s, H-18), 1.09 (3H, d, J = 7.5
Hz, H-21), 1.50 (3H, d, J = 6.0 Hz, H-6''), 1.61 (3H, d, J =
6.5 Hz, H-6'''), 3.74 (1H, m, H-3), 4.90 (1H, d, J = 7.6 Hz,
H-1'), 5.18 (1H, brs, H-6), 5.77 (1H, brs, H-1'''), 5.87 (1H,
brs, H-1''); 13C-NMR (100 MHz, pyridine-d5) : Table I.
Acid hydrolysis of compound 1
Compound 1 was hydrolysed in 5% H2SO4 under reflux
for 3 h. After neutralization with NH4OH followed by ex-
traction with CHCl3, the aqueous layer was evaporated in
vacuo to give a crude sugar residue. The resulting residue
was analysed by TLC (silica gel, CHCl3-MeOH-H2O (64:
40:8) in comparison with standard sugars. The spots of
the product on TLC were identical to those of D-glucose
(Rf 0.32) and L-rhamnose (Rf 0.51).
Experimental animals
Wistar rats of either sex, aged between 12 and 16 weeks
and weighing about 200 g obtained from the animal
house of the Faculty of Science, University of Dschang,
were used in these studies. The animals were housed in
colony cages. They were exposed to daily 12 h light-dark
cycle and have free access to standard laboratory diet
and water. The ethic committee of the Cameroon Ministry
of Scientific Research and Technology which has adopted
the guidelines established by the European Union on
Animal Care and Experimentation (CEE Council 86/609),
approved all experimental procedures.
Carrageenan-induced paw edema
The experiment was conducted as described by Winter
et al. (1962). Animals were divided in 10 groups of 6 rats
each. Groups 1 ad 2 served as negative controls and
received vehicles (distilled water, control1 and the mixture
of 2.5% DMSO and 2.5% tween 80, control2). Groups 3
and 4 (positive controls) received indomethacin (10 mg/
kg) and aspirin (10 mg/kg) respectively. Groups 5 and 6
were treated respectively with the ethanol and n-butanol
extracts at the dose of 600 mg/kg. Groups 7–10 received
compounds 1 to 4 at the dose of 10 mg/kg. All the
treatments were administered orally thirty minutes prior to
the administration of 0.1 mL of carrageenan (1%, sub-
plantarly). The volume of the paw was measured before
treatments (V0) and 0.5, 1, 2, 3, 4, 5 and 6 h after carra-
geenan injection (Vt) with the aid of a Ugo Basil Plethys-
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Fig. 1. Structures of the isolated compounds
3
mometer (7510). The edema was expressed as an
increase in the volume of paw, and the percentage of
inhibition for each rat and group was obtained as follow
(Lanhers et al, 1991):
RESULTS AND DISCUSSION
Compound 1 was obtained as a white amorphous powder.
Its ESIMS (positive mode) showed the pseudomolecular
[M+Na]+ ion peak at m/z 761 corresponding to the mole-
cular formula C39H62O13. The glycoside nature of 3 was
shown by strong IR absorptions at 3325 and 1051 cm-1
characteristic of hydroxyl groups and glycosidic linkages
respectively (Dong et al., 2001). The 13C-NMR spectrum
showed 39 signals (Table I) among which 27 were assign-
ed to the aglycone; the remaining 12 signals were indica-
tive of the presence of two hexoses. The salient features
of this spectrum were the presence of three signals at 
140.7 (C-5), 121.7(C-6) and 109.7(C-22) characteristic of

5-spirostene type sapogenin (Agrawal et al. 1985). The
structure of the aglycone moiety was recognized to be
pennogenin (3,17-dihydroxyspirost-5-ene) by 1H- and
13C-NMR analysis (Table I) using connectivities observed
in 1H-1H COSY, HMQC and HMBC spectra and was in full
agreement with the literature data (Mahato et al., 1981;
Hufford et al., 1988). TLC of the mild acid hydrolyzed 1
revealed the presence of glucose and rhamnose. Two
anomeric carbon atoms detected at  102.9 (C-1'') and
102.2 (C-1') in the 13C-NMR spectrum, were shown to be
attached to proton signals at  6.10 (1H, brs) and 4.76
(1H, d, J = 7.5 Hz), respectively, in the HSQC experiment.
The ring proton of each monosaccharide residue was
assigned starting from the readily identifiable anomeric
proton using 1H-1H COSY spectrum. Analysis of 2D ex-
periments (1H-1H COSY, HSQC and HMBC) followed by
comparison of 1H- and 13C-NMR data of the sugar moiety
with those reported in the literature (Dong et al., 2001;
Hufford et al., 1988; Teponno et al., 2006) revealed the
presence of an inner glucopyranosyl residue and a terminal
rhamnose (Table I). The coupling constants observed for
the two anomeric proton signals at 4.76 (1H, d, J = 7.5
Hz) and 6.10 (1H, brs) suggested that the linkages of the
glucose and rhamnose were of the  and  forms, respec-
tively. The sequence of the sugar chains were obtained by
HMBC experiment. Cross peak correlation observed in
the HMBC spectrum between the anomeric proton at H
Percentage of inhibition
Vt V0–	 
 control Vt V0–	 
 exxay–
Vt V0–	 
 control
-------------------------------------------------------------------------------- 100=
Table II. Effects of aspirin, indomethacin, extracts and pennogenin derivatives from Dracaena mannii on rat hind paw edema induced by
carrageenan
Group
Dose
(mg/kg)
V (mL) (Percentage inhibition)
0.5 h 1 h 2 h 3 h 4 h 5 h 6 h
Control1 - 0.46 ± 0.12 0.81 ± 0.16 1.27 ± 0.23 1.90 ± 0.23 2.06 ± 0.21 1.99 ± 0.29 1.80 ± 0.22
Aspirin 10
0.83 ± 0.10
(31.76%)
1.07 ± 0.11
(41.43%)
1.29 ± 0.13
(49.51%)
1.69 ± 0.12
(40.25%)
1.97 ± 0.16
(32.32%)
2.04 ± 0.11
(30.89%)
1.90 ± 0.12
(30.38%)
Indométhacin 10
0.79 ± 0.08
(20%)
1.10 ± 0.08
(21.43%)
0.98 ± 0.06
(52.43%)
0.93 ± 0.09c
(60.99%)
0.98 ± 0,10c
(62.36%)
1.32 ± 0.11
(49.03%)
1.58 ± 0.04c
(32.91%)
Control2 - 0.84 ± 0.14 1.39 ± 0.19 2.05 ± 0.13 2.41 ± 0.12 2.62 ± 0.07 2.58 ± 0.10 2.36 ± 0.11
Ethanol extract 600
0.59 ± 0,09
(54.76%)
0.55 ± 0.09
(74.10%)
0.71 ± 0.09
(70.73%)
1.29 ± 0.09
(53.94%)
1.08 ± 0.06
(58.78%)
1.20 ± 0,13
(62.01%)
1.03 ± 0,10ã
(56.35%)
n-butanol extract 600
0.38 ± 0.02
(29.76%)
0.36 ± 0.05
(60.43%)
0.60 ± 0.08
(65.36%)
1.11 ± 0.09
(46.47%)
1.08 ± 0.13
(58.78%)
0.98 ± 0.12
(53.49%)
1.03 ± 0.06ã
(56.35%)
1 10
0.38 ± 0.13
(54.76%)
0.27 ± 0.10
(80.57%)
0.74 ± 0.07
(63.90%)
1.17 ± 0.02
(51.45%)
1.12 ± 0.06
(57.25%)
1.11 ± 0.08
(56.98%)
0.85 ± 0.04ã
(63.98%)
2 10 1.09 ± 0.14
(- 29.76%)
0.97 ± 0.14
(30.21%)
1.79 ± 0.09
(12.68%)
2.17 ± 0.10
(9.96%)
2.19 ± 0.16
(16.41%)
2.12 ± 0.06
(17.83%)
2.04 ± 0,10
(13.56%)
3 10
0.42 ± 0.12
(50%)
0.40 ± 0.10
(71.22%)
0.40 ± 0.10
(54.15%)
1.40 ± 0.09
(41.91%)
1.59 ± 0.22
(39.31%)
1.45 ± 0.21
(43.80%)
1.21 ± 0.14
(53.99%)
4 10
0.44 ± 0.10
(47.62%)
0.47 ± 0.07
(66.19%)
1.20 ± 0.17â
(41.46%)
1.85 ± 0.20
(23.24%)
1.76 ± 0.13
(32.82%)
1.70 ± 0.04
(34.11%)
1.57 ± 0.09
(33.47%)
Each value represents the mean ± SEM of 6 animals; cP < 0.001 statistically significant compared to negative control1. P < 0.05; P < 0.01; P <
0.0001. Statistically significant compared to negative control2.
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4.76 (H-1') and the carbon atom at C 78.1 (C-3) showed
that the glucopyranosyl moiety is linked at C-3 of the
aglycone. The cross peak correlation observed between
the signal of the anomeric proton at H 6.10 (H-1'') and the
carbon atom of the glucopyranosyl moiety at C 83.5 (C-
3') suggested the location of the rhamnopyranosyl unit at
C-3'. The common D-configuration for glucose and L-
configuration for rhamnose were assumed to be those of
the most commonly encountered analogues in the plant
kingdom. Thus, the structure of compound 1 was elucidated
as pennogenin-3-O--L-rhamnopyranosyl-(13)--D-glu-
copyranoside, a new natural secondary metabolite to
which we assigned the trivial name mannioside A.
Compound 2 was isolated as white amorphous powder.
It was identified as pennogenin by comparison of the ESI-
MS, 1H- and 13C-NMR data with those previously reported
in the literature (McAnuff et al., 2005). Compounds 3 and
4 were also obtained as white amorphous powders. They
were respectively identified as pennogenin-3-O--D-glu-
copyranoside (floribundasaponin A) and pennogenin-3-O-
-L-rhamnopyranosyl-(12)-[-L-rhamnopyranosyl-(13)]-
-D-glucopyranoside (spiroconazole A) by comparison of
their ESIMS, 1H- and 13C-NMR data with those previously
reported in the literature (Mahato et al., 1981; Teponno et
al., 2006).
The sub-plantar injection of the carrageenan produced
an inflammatory edema which increased gradually, re-
aching its maximum at the 4th hour after injection of the
phlogistic agent (Table II). All the extracts presented signi-
ficant (P < 0.001) anti-inflammatory effects with maximum
activity observed within 2 h. The ethanol and the n-butanol
extracts exhibited an inhibitory percentage of 74 and 65%,
respectively. The tested compounds showed, one hour
after carrageenan injection, a maximum inhibitory activity
of 80.57%, 71.22%, 66.19%, and 30.21% for compounds
1, 3, 4 and 2, respectively. Although reduced, the signi-
ficant activity was maintained during all the experimental
period for compounds 1, 3 and 4. The indomethacin pro-
duced an anti-inflammatory activity which increased grad-
ually to reach a maximum of inhibition (62.36%, P < 0.001)
at the 4th hour.
Additional information could be deduced from the struc-
ture-activity relationship of the tested pennogenin gly-
cosides. Globally all the pennogenin glycosides (1, 3 and
4) were more potent than pennogenin (2). Attachment of
D-glucose to pennogenin was observed to significantly
improve (from 30.21% to 71.22% edema reduction) the
anti-inflammatory activity (compound 3). One sugar moiety
(rhamnose) substitution to C-3 of D-glucose in compound
1 led to a little higher activity (from 71.22% to 80.57%
edema reduction) than that of compound 3 whereas, in
compound 4, two rhamnose moieties attached at both
sites of C-2 and C-3 of D-glucose in compound 3 slightly
reduced the activity (from 71.22% to 66.19% edema
reduction).
Although further studies are needed to ascertain the
biomedical and molecular mechanisms underlying the anti-
inflammatory activity of these compounds, the present
study has documented the anti-inflammatory properties of
Dracaena mannii stem bark. Furthermore, it has been
demonstrated that pennogenin glycosides play a signifi-
cant role in the overall anti-inflammatory response induced
by this plant. 
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